论文部分内容阅读
目的探讨原发性乳腺癌组织中nm23基因的表达及其意义。方法采用免疫组织化学S-P法检测286例原发性乳腺癌nm23基因表达情况并与乳腺癌病理类型、患者年龄、临床分期及腋淋巴结转移之间的关系进行分析。结果nm23的阳性率为65.7%,与病人年龄、肿瘤病理类型无关;肿瘤临床分期越高,nm23的阳性率越低;腋淋巴结转移组的nm23阳性率明显低于腋淋巴结无转移组(P<0.05)。结论乳腺癌组织中nm23基因表达与乳腺癌临床分期、腋淋巴结转移呈负相关,提示nm23基因可作为预测原发性乳腺癌淋巴结转移和评估肿瘤临床预后的标记物。
Objective To investigate the expression of nm23 gene in primary breast cancer and its significance. Methods The expression of nm23 gene in 286 cases of primary breast cancer was detected by immunohistochemical S-P method. The relationship was analyzed with the pathological type, age, clinical stage and axillary lymph node metastasis of breast cancer. Results The positive rate of nm23 was 65.7%, which was not related to the patient’s age and tumor pathology. The higher the clinical stage was, the lower the positive rate of nm23 was. The positive rate of nm23 in axillary lymph node metastasis was significantly lower than that in axillary lymph node metastasis (P < 0.05). Conclusion The expression of nm23 in breast cancer tissue is negatively correlated with the clinical stage and axillary lymph node metastasis of breast cancer, suggesting that nm23 gene may be used as a marker for predicting lymph node metastasis of primary breast cancer and evaluating the clinical prognosis of breast cancer.